Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01519414 · ClinicalTrials.gov registry record · Phase 2
Tivantinib in Treating Patients With Metastatic Prostate Cancer
A Phase 2 study of Prostate Adenocarcinoma and Recurrent Prostate Carcinoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 20
- Study locations
NCT01519414 is a Phase 2 study of Prostate Adenocarcinoma and Recurrent Prostate Carcinoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 78 participants, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT01519414, a Phase 2 study of Prostate Adenocarcinoma and Recurrent Prostate Carcinoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase II trial studies how well tivantinib works compared to placebo in treating patients with metastatic prostate cancer. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- DRUG Tivantinib
Study Locations (20)
Illinois
- Northwestern University - Chicago
- Michael Reese Hospital - Chicago
- University of Chicago Comprehensive Cancer Center - Chicago
- Decatur Memorial Hospital - Decatur
- NorthShore University HealthSystem-Evanston Hospital - Evanston
- Ingalls Memorial Hospital - Harvey
- Illinois CancerCare-Peoria - Peoria
- Southern Illinois University School of Medicine - Springfield
Ohio
- Case Western Reserve University - Cleveland
- Cleveland Clinic Foundation - Cleveland
- Ohio State University Comprehensive Cancer Center - Columbus
Indiana
- Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard - Fort Wayne
- Indiana University/Melvin and Bren Simon Cancer Center - Indianapolis
Maryland
- University of Maryland/Greenebaum Cancer Center - Baltimore
- University of Maryland Saint Joseph Medical Center - Towson
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Florida
- Moffitt Cancer Center - Tampa
Missouri
- Mercy Hospital Saint Louis - St Louis
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2012-01-11 |
| Est. Completion | 2015-08-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01519414
The ClinicalTrials.gov registry entry for NCT01519414 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (64% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01519414 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Illinois, Ohio, Indiana.
Frequently Asked Questions
What is clinical trial NCT01519414 about?
NCT01519414 is a clinical study titled "Tivantinib in Treating Patients With Metastatic Prostate Cancer". This randomized phase II trial studies how well tivantinib works compared to placebo in treating patients with metastatic prostate cancer. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01519414?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2012-01-11. Estimated completion is 2015-08-18.
What conditions does trial NCT01519414 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Resistant Prostate Cancer.
What interventions are being tested in trial NCT01519414?
The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Tivantinib (DRUG).
Who is sponsoring clinical trial NCT01519414?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01519414 being conducted?
This trial has 20 study locations across District of Columbia, Florida, Illinois, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
RECRUITING · Phase 2
-
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 2
-
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
RECRUITING · Phase 2
-
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
RECRUITING · Phase 2
-
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Prostate Adenocarcinoma
All registered trials for this condition
Recurrent Prostate Carcinoma
All registered trials for this condition
District of Columbia
All trials with a study site in District of Columbia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.